Correction

Osteonecrosis of the Jaw and Bisphosphonates

N Engl J Med 2005; 353:2728December 22, 2005

Article

Osteonecrosis of the Jaw and Bisphosphonates (Correspondence, N Engl J Med 2005:353;99 - 102) . On page 101, lines 5 through 8 of the letter by Tarassoff and Hei should have read, “As the developer of Aredia (pamidronate) and Zometa (zoledronic acid), we have implemented labeling revisions for these two drugs with the approval of the Food and Drug Administration and based on best clinical judgment,” rather than “. . . we have obtained expert advice on how to revise the labels for these two drugs,” as printed.